Regeneron, Sanofi win a delayed OK for rheumatoid arthritis IL-6 heavyweight sarilumab
It took more than six months and likely caused more than a few red faces, but Sanofi has dealt with the FDA’s issues with its manufacturing ops and won a green light to start marketing the likely blockbuster sarilumab alongside its partners at Regeneron.
Consensus peak sales forecasts on the drug — to be marketed as Kevzara — top the $1 billion blockbuster mark, making it a big addition for both companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.